Spots Global Cancer Trial Database for Randomised Study Comparing Three Chemotherapy Regimens in Non-small Cell Lung Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Randomised Study Comparing Three Chemotherapy Regimens in Non-small Cell Lung Cancer
Official Title: A Phase III Randomised Study Comparing Three Combination Chemotherapy Regimens in Patients With Non Pre-treated Advanced Non-small Cell Lung Cancer
Study ID: NCT00622349
Conditions
Study Description
Brief Summary: The purpose of this study is to determine if cisplatin-based chemotherapy, cisplatin-gemcitabine-ifosfamide or cisplatin-docetaxel, will improve survival in comparison to the combination gemcitabine-ifosfamide in patients with advanced NSCLC
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Department of Intensive Care Unit and Thoracic Oncology Institut Jules Bordet, Brussels, , Belgium
Pneumology department of CHU Lille, Lille, , France
Hellenic Cancer Institute - St Savas Oncology Hospital, Athens, , Greece
Medical Oncology Hospital de Sagunto, Valencia, , Spain
Contact Details
Name: Jean-Paul Sculier, MD, PhD
Affiliation: European Lung Cancer Working Party
Role: STUDY_CHAIR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
